256 related articles for article (PubMed ID: 35331284)
1. The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers.
Tylki-Szymańska A; Almássy Z; Christophidou-Anastasiadou V; Avdjieva-Tzavella D; Barisic I; Cerkauskiene R; Cuturilo G; Djiordjevic M; Gucev Z; Hlavata A; Kieć-Wilk B; Magner M; Pecin I; Plaiasu V; Samardzic M; Zafeiriou D; Zaganas I; Lampe C
Orphanet J Rare Dis; 2022 Mar; 17(1):136. PubMed ID: 35331284
[TBL] [Abstract][Full Text] [Related]
2. Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries.
Magner M; Almássy Z; Gucev Z; Kieć-Wilk B; Plaiasu V; Tylki-Szymańska A; Zafeiriou D; Zaganas I; Lampe C
Orphanet J Rare Dis; 2022 May; 17(1):190. PubMed ID: 35538504
[TBL] [Abstract][Full Text] [Related]
3. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
[TBL] [Abstract][Full Text] [Related]
4. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
[TBL] [Abstract][Full Text] [Related]
5. Cardiac involvement in MPS patients: incidence and response to therapy in an Italian multicentre study.
Sestito S; Rinninella G; Rampazzo A; D'Avanzo F; Zampini L; Santoro L; Gabrielli O; Fiumara A; Barone R; Volpi N; Scarpa M; Tomanin R; Concolino D
Orphanet J Rare Dis; 2022 Jun; 17(1):251. PubMed ID: 35768874
[TBL] [Abstract][Full Text] [Related]
6. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy.
Donida B; Marchetti DP; Biancini GB; Deon M; Manini PR; da Rosa HT; Moura DJ; Saffi J; Bender F; Burin MG; Coitinho AS; Giugliani R; Vargas CR
Biochim Biophys Acta; 2015 May; 1852(5):1012-9. PubMed ID: 25701642
[TBL] [Abstract][Full Text] [Related]
8. Cerebral magnetic resonance findings during enzyme replacement therapy in mucopolysaccharidosis.
Matsubara Y; Miyazaki O; Kosuga M; Okuyama T; Nosaka S
Pediatr Radiol; 2017 Nov; 47(12):1659-1669. PubMed ID: 28733853
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory process and oxidative/nitrative stress: in vivo study in mucopolysaccharidosis type IV A patients under long-term enzyme replacement therapy.
Aguilar Delgado C; Hammerschmidt T; Faverzini JL; Lopes F; Giugliani R; Baldo G; Vargas CR
Arch Biochem Biophys; 2023 Mar; 737():109541. PubMed ID: 36754222
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.
Akyol MU; Alden TD; Amartino H; Ashworth J; Belani K; Berger KI; Borgo A; Braunlin E; Eto Y; Gold JI; Jester A; Jones SA; Karsli C; Mackenzie W; Marinho DR; McFadyen A; McGill J; Mitchell JJ; Muenzer J; Okuyama T; Orchard PJ; Stevens B; Thomas S; Walker R; Wynn R; Giugliani R; Harmatz P; Hendriksz C; Scarpa M; ;
Orphanet J Rare Dis; 2019 Jun; 14(1):137. PubMed ID: 31196221
[TBL] [Abstract][Full Text] [Related]
11. Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management.
Sawamoto K; Álvarez González JV; Piechnik M; Otero FJ; Couce ML; Suzuki Y; Tomatsu S
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102177
[TBL] [Abstract][Full Text] [Related]
12. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.
Tomatsu S; Sawamoto K; Alméciga-Díaz CJ; Shimada T; Bober MB; Chinen Y; Yabe H; Montaño AM; Giugliani R; Kubaski F; Yasuda E; Rodríguez-López A; Espejo-Mojica AJ; Sánchez OF; Mason RW; Barrera LA; Mackenzie WG; Orii T
Drug Des Devel Ther; 2015; 9():1937-53. PubMed ID: 25897204
[TBL] [Abstract][Full Text] [Related]
13. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment.
Tomatsu S; Montaño AM; Oikawa H; Smith M; Barrera L; Chinen Y; Thacker MM; Mackenzie WG; Suzuki Y; Orii T
Curr Pharm Biotechnol; 2011 Jun; 12(6):931-45. PubMed ID: 21506915
[TBL] [Abstract][Full Text] [Related]
14. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders.
Miebach E
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S100-6. PubMed ID: 20040319
[TBL] [Abstract][Full Text] [Related]
15. Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries.
Solano VM; Mandujano CYC; Avila-Rejon CA; Espin VH; Montaño HPQ
Mol Genet Metab Rep; 2021 Sep; 28():100769. PubMed ID: 34113545
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of dipeptidyl peptidase-IV (DPP-IV) activity in patients with mucopolysaccharidoses types I and II on enzyme replacement therapy - Results of a pilot study.
Hetmańczyk K; Bednarska-Makaruk M; Kierus K; Murawska-Izdebska S; Piekutowska-Abramczuk D; Pilch B; Tylki-Szymańska A; Ługowska A
Clin Biochem; 2016 Apr; 49(6):458-462. PubMed ID: 26592960
[TBL] [Abstract][Full Text] [Related]
17. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
[TBL] [Abstract][Full Text] [Related]
18. Elosulfase alfa.
Haddley K
Drugs Today (Barc); 2014 Jul; 50(7):475-83. PubMed ID: 25101330
[TBL] [Abstract][Full Text] [Related]
19. Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.
Losada Díaz JC; Cepeda Del Castillo J; Rodriguez-López EA; Alméciga-Díaz CJ
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905715
[TBL] [Abstract][Full Text] [Related]
20. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI.
Lin HY; Chuang CK; Chen MR; Lin SM; Hung CL; Chang CY; Chiu PC; Tsai WH; Niu DM; Tsai FJ; Lin SJ; Hwu WL; Lin JL; Lin SP
Mol Genet Metab; 2016 Apr; 117(4):431-7. PubMed ID: 26899310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]